Celgene Says Phase 3 Study of Otezla Met Primary Endpoint
October 08 2018 - 5:44PM
Dow Jones News
By Stephen Nakrosis
Celgene Corp. (CELG) said Monday results from the phase 3 STYLE
study showed Otezla achieved a highly statistically significant
improvement in the primary endpoint of the Scalp Physician's Global
Assessment response after 16 weeks when compared with a
placebo.
Otezla is for use by patients with moderate to severe plaque
psoriasis.
The company also said statistical significance was met for the
secondary endpoint of the whole body itch numeric rating scale at
week 16.
Terrie Curran, president of Celgene's inflammation and
immunology operations, said the company was "encouraged by the
significant improvements in this trial and look forward to sharing
these data to further enhance the Otezla label."
Celgene said the safety profile was generally consistent with
the known safety profile of Otezla, and no new safety signals were
identified in the trial.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 08, 2018 17:29 ET (21:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Oct 2023 to Oct 2024